1 to 10 of 36
Sort by

Library Entry
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment

Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. The authors applied mass spectrometry (MS) immunopeptidomics to investigate neoantigen presentation and whether this can be augmented...

Library Entry
Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status

Analysis of deficiency in DNA mismatch repair (dMMR) is currently considered a standard molecular test in all patients with colorectal cancer (CRC) for its implications in screening, prognosis and prediction of benefit from immune checkpoint inhibitors. While the molecular heterogeneity of CRC...

Library Entry
Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling

Colorectal cancer (CRC) is one of the most common forms of cancer worldwide. The tumor microenvironment plays a key role in promoting the occurrence of chemoresistance in solid cancers. Effective targets to overcome resistance are necessary to improve the survival and prognosis of CRC patients....

Library Entry
miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer

Indoleamine 2,3-dioxygenase 1 (IDO1) is a critical regulator of T cell function, contributing to immune tolerance. Upregulation of IDO1 has been found in many cancer types; however, the regulatory mechanisms and clinical significance of IDO1 in colon cancer are still unclear. Here, the authors...

Library Entry
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination

Radiotherapy (RT) induces an immunogenic antitumor response, but also some immunosuppressive barriers. It remains unclear how different fractionation protocols can modulate the immune microenvironment. The authors sought to characterize the effect of different fractionation protocols on immune...

Library Entry
Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes

Type I interferons (IFN-I) have recently emerged as key regulators of tumor response to chemotherapy and immunotherapy. However, IFN-I function in cytotoxic T lymphocytes (CTLs) in the tumor microenvironment is largely unknown. IFN-I induces STAT3 activation to activate Gzmb expression to...

Library Entry
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics

Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with potential to provide greater clinical benefit to patients with advanced-stage cancer. In particular, recombinant vaccinia viruses (VV) hold great promise as interventional agents. In this article, the authors...

Library Entry
EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

Toll-like receptor 9 agonists are potent activators of the immune system. Their clinical potential in immunotherapy against metastatic cancers is being evaluated across a number of clinical trials. TLR9 agonists are DNA-based molecules that contain several non-methylated CG-motifs for TLR9...

Library Entry
SITC 2018 Annual Meeting: Plenary Session 207: Presidential Session

The Society for Immunotherapy of Cancer (SITC) hosted "Plenary Session 207: Presidential Session" during the SITC 2018 Annual Meeting on November 10, 2018. Available here are the presentation slides and video from the session. 33 rd Annual Meeting Organizers Crystal L. Mackall, MD –...

5 attachments